Stocks · News reference
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Aurinia Pharmaceuticals Inc. (AUPH)
Filed: 2026-08-19 AccNo: 0001600620-26-000066 Size: 177 KB Item 8.01: Other Events
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva Pharmaceuticals Inc.
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48
UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.
Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
Teva reports positive Phase 2a results for TEV '408, successfully preventing gluten-induced intestinal damage in adult celiac patients.
Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
Teva Pharma is trading higher after announcing positive topline results from a Phase 2a study of TEV '408, which met its primary endpoint.